title: Potentiation of oxycodone antinociception in mice by agmatine and BMS182874 via an imidazoline I2 receptor-mediated mechanism.
abstract: The potentiation of oxycodone antinociception by BMS182874 (endothelin-A (ET(A)) receptor antagonist) and agmatine (imidazoline receptor/α(2)-adrenoceptor agonist) is well-documented. It is also known that imidazoline receptors but not α(2)-adrenoceptors are involved in potentiation of oxycodone antinociception by agmatine and BMS182874 in mice. However, the involvement of specific imidazoline receptor subtypes (I(1), I(2), or both) in this interaction is not clearly understood. The present study was conducted to determine the involvement of imidazoline I(1) and I(2) receptors in agmatine- and BMS182874-induced potentiation of oxycodone antinociception in mice. Antinociceptive (tail flick and hot-plate) latencies were determined in male Swiss Webster mice treated with oxycodone, agmatine, BMS182874, and combined administration of oxycodone with agmatine or BMS182874. Efaroxan (imidazoline I(1) receptor antagonist) and BU224 (imidazoline I(2) receptor antagonist) were used to determine the involvement of I(1) and I(2) imidazoline receptors, respectively. Oxycodone produced significant antinociceptive response in mice which was not affected by efaroxan but was blocked by BU224. Agmatine-induced potentiation of oxycodone antinociception was blocked by BU224 but not by efaroxan. Similarly, BMS182874-induced potentiation of oxycodone antinociception was blocked by BU224 but not by efaroxan. This is the first report demonstrating that BMS182874- or agmatine-induced enhancement of oxycodone antinociception is blocked by BU224 but not by efaroxan. We conclude that imidazoline I(2) receptors but not imidazoline I(1) receptors are involved in BMS182874- and agmatine-induced potentiation of oxycodone antinociception in mice.
authors.affiliation: Department of Pharmaceutical Sciences, Chicago College of Pharmacy, Midwestern University, 555 31st Street, Downers Grove, IL 60515, United States. SBHALL@midwestern.edu
authors.forename: Shaifali
authors.initials: S
authors.lastname: Bhalla
authors.forename: Izna
authors.initials: I
authors.lastname: Ali
authors.forename: Hyaera
authors.initials: H
authors.lastname: Lee
authors.forename: Shridhar V
authors.initials: SV
authors.lastname: Andurkar
authors.forename: Anil
authors.initials: A
authors.lastname: Gulati
mesh_terms: D000376:Agmatine / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D000701:Analgesics, Opioid / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D000818:Animals; D001572:Benzofurans / Q000494:pharmacology; D003619:Dansyl Compounds / Q000494:pharmacology*; D004357:Drug Synergism; D007093:Imidazoles / Q000494:pharmacology; D054755:Imidazoline Receptors / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism*; D008297:Male; D051379:Mice; D010098:Oxycodone / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D010147:Pain Measurement
chemical_list: D000701:Analgesics, Opioid; C105826:BU 224; D001572:Benzofurans; D003619:Dansyl Compounds; D007093:Imidazoles; D054755:Imidazoline Receptors; C410887:imidazoline I1 receptors; C487767:imidazoline receptor 2; C085754:5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide; D000376:Agmatine; D010098:Oxycodone; C062597:efaroxan